CoChat
Sign Up
Cited by 71Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDiabetes Treatment and Management

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease

Salles, Geisa Nogueira, Calió, Michele Longoni, Hölscher, Christian, Pacheco-Soares, Cristina, Porcionatto, Marimelia, Lobo, Anderson Oliveira·2020·Neuropharmacology
DOI 10.1016/j.neuropharm.2019.107813
Open this paper in CoChat — free account

Abstract

The sister incretins glucagon-like peptide-1 (GLP-1) and glucagon dependent insulinotropic polypeptide (GIP) are growth factors responsible for re-sensitizing insulin signalling. Interestingly, their analogues, originally developed to treat type 2 diabetes (T2D), have demonstrated a range of neuroprotective and neurorestorative properties. Novel peptide GLP-1/GIP dual agonist (DA) shows good effects in diabetic patients, superior to the effects demonstrated by single GIP or GLP-1 mimetics. Furthermore, novel DAs have shown considerable neuroprotection in neurodegenerative models. Here, we investigated the neuroprotective and restorative involvement of the DA DA-JC1 and liraglutide (Lg), a single GLP-1 receptor analogue, in vitro using human neuroblastoma (SH-SY5Y) against oxidative stress induced by oxygen peroxide (H 2 O 2 ), and in vivo, in a mouse model of Alzheimer's disease (AD), APP/PS1. First, we determined the ideal concentration of the peptides and demonstrated that DA-JC1 protects cells against oxidative stress more than Lg, improving cell viability, normalizing reactive oxygen species (ROS) and attenuating DNA damage generated by H 2 O 2 . Moreover, in 10-to-12-months-old APP/PS1 animals treated for 4 weeks, both Lg and DA-JC1 were very efficient in stimulating neurogenesis and reducing some important hallmarks of AD, but DA-JC1 was better than Lg in attenuating crucial neuroinflammatory markers, especially reactive astrocyte, in both wild-type (WT) and APP/PS1 hip…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2019.107813

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 67

  1. Alzheimer, 1911, Über eigenartige Krankheitsfälle des späteren Alters, Zeitschrift für die gesamte Neurologie und Psychiatrie, 4, 356, 10.1007/BF02866241 · DOI
  2. Aviles-Olmos, 2014, Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease, J. Parkinson's Dis., 4, 337, 10.3233/JPD-140364 · DOI
  3. Batista, 2018, The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non‐human primate model of Alzheimer's disease, J. Pathol., 245, 85, 10.1002/path.5056 · DOI
  4. Bertilsson, 2008, Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease, J. Neurosci. Res., 86, 326, 10.1002/jnr.21483 · DOI · Paper page
  5. Bregenholt, 2005, The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro, Biochem. Biophys. Res. Commun., 330, 577, 10.1016/j.bbrc.2005.03.013 · DOI
  6. Brown, 2003, Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria, Mol. Neurobiol., 27, 325, 10.1385/MN:27:3:325 · DOI
  7. Butterfield, 2006, Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics, Eur. J. Pharmacol., 545, 39, 10.1016/j.ejphar.2006.06.026 · DOI · Paper page
  8. Butterfield, 2014, Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis., 1842, 1693, 10.1016/j.bbadis.2014.06.010 · DOI · Paper page
  9. Cai, 2017, Lixisenatide attenuates the detrimental effects of amyloid β protein on spatial working memory and hippocampal neurons in rats, Behav. Brain Res., 318, 28, 10.1016/j.bbr.2016.10.033 · DOI
  10. Cao, 2016, A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain, Neuroreport, 37, 384, 10.1097/WNR.0000000000000548 · DOI
  11. Cao, 2018, DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease, Eur. J. Pharmacol., 827, 215, 10.1016/j.ejphar.2018.03.024 · DOI
  12. Carvalho, 2016, High doses of alcohol during pregnancy cause DNA damages in osteoblasts of newborns rats, Birth Defects Res. Part A Clin. Mol. Teratol., 106, 122, 10.1002/bdra.23468 · DOI
  13. Cheng, 1994, NT-3 and BDNF protect CNS neurons against metabolic/excitotoxic insults, Brain Res., 640, 56, 10.1016/0006-8993(94)91857-0 · DOI
  14. Chuang, 2010, Neurogenesis in mouse models of Alzheimer's disease, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis., 1802, 872, 10.1016/j.bbadis.2009.12.008 · DOI
  15. Craft, 2012, Alzheimer disease: insulin resistance and AD—extending the translational path, Nat. Rev. Neurol., 8, 360, 10.1038/nrneurol.2012.112 · DOI
  16. Curtis, 2007, The effect of neurodegenerative diseases on the subventricular zone, Nat. Rev. Neurosci., 8, 712, 10.1038/nrn2216 · DOI
  17. Dani, 2018, Microglial activation correlates in vivo with both tau and amyloid in Alzheimer’s disease, Brain, 141, 2740
  18. de la Monte, 2008, Alzheimer's disease is type 3 diabetes—evidence reviewed, J.Diabetes.Sci. Technol., 2, 1101, 10.1177/193229680800200619 · DOI · Paper page
  19. Doetsch, 1996, Network of tangential pathways for neuronal migration in adult mammalian brain, Proc. Natl. Acad. Sci., 93, 14895, 10.1073/pnas.93.25.14895 · DOI
  20. Faivre, 2013, Neuroprotective effects of D-Ala 2 GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model, Alzheimer's Res. Ther., 5, 20, 10.1186/alzrt174 · DOI
  21. Faivre, 2012, Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice, Eur. J. Pharmacol., 674, 294, 10.1016/j.ejphar.2011.11.007 · DOI
  22. Feng, 2018, Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease, Neuropharmacology, 133, 385, 10.1016/j.neuropharm.2018.02.012 · DOI
  23. Flood, 1996, Age-related changes in hippocampal drug facilitation of memory processing in SAMP 8 Mice, Neurobiology of aging, 17, 15, 10.1016/0197-4580(95)02007-1 · DOI
  24. Gage, 2000, Mammalian neural stem cells, Science, 287, 1433, 10.1126/science.287.5457.1433 · DOI · Paper page
  25. Garcia, 2014, Therapeutic effects of the transplantation of VEGF overexpressing bone marrow mesenchymal stem cells in the hippocampus of murine model of Alzheimer's disease, Front. Aging Neurosci., 6, 30, 10.3389/fnagi.2014.00030 · DOI
  26. Gejl, 2016, In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial, Front. Aging Neurosci., 8, 108, 10.3389/fnagi.2016.00108 · DOI · Paper page
  27. Göke, 1995, Distribution of GLP‐1 binding sites in the rat brain: evidence that exendin‐4 is a ligand of brain GLP‐1 binding sites, Eur. J. Neurosci., 7, 2294, 10.1111/j.1460-9568.1995.tb00650.x · DOI · Paper page
  28. Hamilton, 2012, The effect of ageing on neurogenesis and oxidative stress in the APPswe/PS1deltaE9 mouse model of Alzheimer's disease, Brain Res., 1449, 83, 10.1016/j.brainres.2012.02.015 · DOI
  29. Hansen, 2015, The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer's disease, J. Alzheimer's Dis., 46, 877, 10.3233/JAD-143090 · DOI
  30. Heneka, 2015, Neuroinflammation in Alzheimer's disease, Lancet Neurol., 14, 388, 10.1016/S1474-4422(15)70016-5 · DOI · Paper page
  31. Hölscher, 2014, The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease, Alzheimer's Dementia, 10, S47
  32. Hölscher, 2018, Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer’s and Parkinson’s disease models, Neuropharmacology, 136, 251, 10.1016/j.neuropharm.2018.01.040 · DOI
  33. Huang, 2016, Role of oxidative stress in Alzheimer's disease, Biomedical reports, 4, 519, 10.3892/br.2016.630 · DOI · Paper page
  34. Jalewa, 2017, A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease, Neuropharmacology, 117, 238, 10.1016/j.neuropharm.2017.02.013 · DOI
  35. Ji, 2016, A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson′ s disease by increasing expression of BNDF, Brain Res., 1634, 1, 10.1016/j.brainres.2015.09.035 · DOI
  36. Kovalevich, 2013, Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology, Neuronal Cell Culture: Methods.Protoc., 9, 10.1007/978-1-62703-640-5_2 · DOI · Paper page
  37. Lovshin, 2009, Incretin-based therapies for type 2 diabetes mellitus, Nat. Rev. Endocrinol., 5, 262, 10.1038/nrendo.2009.48 · DOI
  38. Lucin, 2009, Immune activation in brain aging and neurodegeneration: too much or too little?, Neuron, 64, 110, 10.1016/j.neuron.2009.08.039 · DOI · Paper page
  39. Mansur, 2017, Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study, J. Affect. Disord., 207, 114, 10.1016/j.jad.2016.09.056 · DOI
  40. Markesbery, 1997, Oxidative stress hypothesis in Alzheimer's disease, Free Radic. Biol. Med., 23, 134, 10.1016/S0891-5849(96)00629-6 · DOI · Paper page
  41. McClean, 2011, The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease, J. Neurosci., 31, 6587, 10.1523/JNEUROSCI.0529-11.2011 · DOI · Paper page
  42. Nichols, 1993, GFAP mRNA increases with age in rat and human brain, Neurobiology of aging, 14, 421, 10.1016/0197-4580(93)90100-P · DOI · Paper page
  43. Nyberg, 2005, Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation, J. Neurosci., 25, 1816, 10.1523/JNEUROSCI.4920-04.2005 · DOI · Paper page
  44. Nyberg, 2007, Immunohistochemical distribution of glucose‐dependent insulinotropic polypeptide in the adult rat brain, J. Neurosci. Res., 85, 2099, 10.1002/jnr.21349 · DOI
  45. Panagaki, 2018, The novel DA–CH3 dual incretin restores endoplasmic reticulum stress and autophagy impairments to attenuate alzheimer-like pathology and cognitive decrements in the APP SWE/PS1 ΔE9 mouse model, J. Alzheimer's Dis., 1
  46. Polster, 2014, Use of potentiometric fluorophores in the measurement of mitochondrial reactive oxygen species, vol. 547, 225
  47. Qin, 2008, Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-β peptide (1–42), Neurosci. Lett., 444, 217, 10.1016/j.neulet.2008.08.047 · DOI
  48. Rodríguez, 2009, Impaired cell proliferation in the subventricular zone in an Alzheimer's disease model, Neuroreport, 20, 907, 10.1097/WNR.0b013e32832be77d · DOI
  49. Roelofs, 2015, Low micromolar concentrations of the superoxide probe MitoSOX uncouple neural mitochondria and inhibit complex IV, Free Radic. Biol. Med., 86, 250, 10.1016/j.freeradbiomed.2015.05.032 · DOI
  50. Salles, 2017, A novel bioresorbable device as a controlled release system for protecting cells from oxidative stress from Alzheimer's Disease, Mol. Neurobiol., 54, 6827, 10.1007/s12035-016-0200-0 · DOI
  51. Salles, 2017, Novel BIODEVICE releases drug IN VIVO for 14 days and avoids DNA damage IN stress-induced neuroblastoma cells: a promise for ALZHEIMER'S disease treatment, Alzheimer's Dementia: J. Alzheimer's.Assoc., 13, P955
  52. Salles, 2018, Prolonged drug releasing fibers attenuate Alzheimer’s disease-like pathogenesis, ACS Appl. Mater. Interfaces, 10, 36693, 10.1021/acsami.8b12649 · DOI
  53. Salles, 2018, Dual incretin agonist reduces neuroinflammation IN a transgenic mouse model OF ALZHEIMER’S disease, Alzheimer's Dementia: J. Alzheimer's.Assoc., 14, P1453
  54. Seino, 2010, GIP and GLP‐1, the two incretin hormones: similarities and differences, J. Diabetes.Investig., 1, 8, 10.1111/j.2040-1124.2010.00022.x · DOI · Paper page
  55. Sharma, 2014, Neuroprotective and anti‐apoptotic effects of liraglutide on SH‐SY5Y cells exposed to methylglyoxal stress, J. Neurochem., 128, 459, 10.1111/jnc.12469 · DOI · Paper page
  56. Shibata, 2008, The role for oxidative stress in neurodegenerative diseases, Brain and nerve= Shinkei kenkyu no shinpo, 60, 157
  57. Simpson, 2010, Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain, Neurobiology of aging, 31, 578, 10.1016/j.neurobiolaging.2008.05.015 · DOI · Paper page
  58. Sonnen, 2008, Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models, Free Radic. Biol. Med., 45, 219, 10.1016/j.freeradbiomed.2008.04.022 · DOI
  59. Spielman, 2017, Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors, Eur. J. Cell Biol., 96, 240, 10.1016/j.ejcb.2017.03.004 · DOI
  60. Taupin, 2006, Therapeutic potential of adult neural stem cells, Recent Pat. CNS Drug Discov., 1, 299, 10.2174/157488906778773670 · DOI
  61. Unger, 2016, Early changes in hippocampal neurogenesis in transgenic mouse models for Alzheimer's disease, Mol. Neurobiol., 53, 5796, 10.1007/s12035-016-0018-9 · DOI
  62. Wang, 2018, Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus, Epilepsy Res., 142, 45, 10.1016/j.eplepsyres.2018.03.009 · DOI
  63. Yabe, 2011, Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation, Prog. Biophys. Mol. Biol., 107, 248, 10.1016/j.pbiomolbio.2011.07.010 · DOI
  64. Yu, 2016, Glucose-dependent insulinotropic polypeptide ameliorates mild traumatic brain injury-induced cognitive and sensorimotor deficits and neuroinflammation in rats, J. Neurotrauma, 33, 2044, 10.1089/neu.2015.4229 · DOI
  65. Yuan, 2017, A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease, Eur. J. Pharmacol., 812, 82, 10.1016/j.ejphar.2017.06.029 · DOI
  66. Zhao, 2008, Mechanisms and functional implications of adult neurogenesis, Cell, 132, 645, 10.1016/j.cell.2008.01.033 · DOI · Paper page
  67. Ziabreva, 2006, Altered neurogenesis in Alzheimer's disease, J. Psychosom. Res., 61, 311, 10.1016/j.jpsychores.2006.07.017 · DOI

Cited by

Sorted by citations

Metadata

Authors
Salles, G. N., Calió, M. L., Hölscher, C., Pacheco-Soares, C., Porcionatto, M., & Lobo, A. O.
Affiliations
  • Universidade do Vale do Paraíba (BR)
  • Universidade Federal de São Paulo (BR)
  • Henan University of Chinese Medicine (CN)
  • Universidade Federal do Piauí (BR)
Corresponding author
Lobo, Anderson Oliveira
ORCID
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2020-01
Volume
162
Pages
107813
ISSN
0028-3908 (ISSN-L)
DOI
10.1016/j.neuropharm.2019.107813
OpenAlex
W2980357598
Cited by
71
References
11
Citations by year
2026: 7 · 2025: 12 · 2024: 14 · 2023: 6 · 2022: 17 · 2021: 9 · 2020: 6
FWCI
3.18
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Neuropharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (2014/20561-0)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (404683/2018-5, 303752/2017-3)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
GIP/GLP-1 receptor agonist, liraglutide, Alzheimer's disease, neuroprotection, neurorestoration, incretins, oxidative stress, reactive oxygen species, DNA damage, neuroinflammation, reactive astrocytes, neurogenesis, APP/PS1 mice, SH-SY5Y cells, hippocampus, GLP-1 receptor
MeSH terms
Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Alzheimer Disease, Animals, Brain, Cell Survival, DNA Damage, Hippocampus, Humans, Hydrogen Peroxide, Mice, Transgenic, Neurons, Peptides, Receptors, Gastrointestinal Hormone, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Oxidative Stress, Neuroprotective Agents, Lateral Ventricles, Cell Line, Tumor, Mice, Presenilin-1, Incretins, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review